Table 2.
OCIAD2 gene expression and clinicopathological features in patients with pulmonary adenocarcinoma
| Clinicopathological features | All patients | OCIAD2 expression in in situ hybridization | P‐value | |
|---|---|---|---|---|
| No. positive (%) | No. negative (%) | |||
| All patients | 56 | 34 | 22 | |
| Mean age (years) | 65.7 | 67.53 | 62.91 | |
| Sex | ||||
| Male | 31 | 17 (54.8) | 14 | |
| Female | 25 | 17 (68) | 8 | 0.316 |
| Pathological stage | ||||
| Stage I | 34 | 25 (73.5) | 9 | |
| Stage II | 3 | 1 (33.3) | 2 | |
| Stage III | 17 | 7 (41.2) | 10 | |
| Stage IV | 2 | 1 (50.0) | 1 | 0.107 |
| Ly factor | ||||
| Negative | 32 | 24 (75.0) | 8 | |
| Positive | 24 | 10 (41.7) | 14 | 0.011* |
| V factor | ||||
| Negative | 39 | 29 (74.4) | 10 | |
| Positive | 17 | 5 (29.4) | 12 | 0.002* |
| Lymph node status | ||||
| N0 | 40 | 29 (72.5) | 11 | |
| N1 and N2 | 16 | 5 (31.3) | 11 | 0.012* |
Stage I includes IA and IB, stage II includes IIA and IIB, stage III includes IIIA and IIIB. Ly factor, lymphatic vessel invasion; N factor, lymph node involvement; V factor, vascular vessel invasion. *The difference was statistically significant (P < 0.05).